Article by Peter Lenehan, MD, ’84, SUNY Downstate alumnus: Generation and External Validation
One in 4 patients with lymph node-negative, invasive colorectal carcinoma (CRC) develops recurrent disease after undergoing curative surgery, and most die of advanced disease. Predicting which patients will develop a recurrence is a significantly growing, unmet medical need.
To the authors’ knowledge, the 5-gene rule (OncoDefender-CRC) is the first molecular prognostic that has been validated in both stage I CRC and stage II colon cancer. It outperforms standard clinicopathologic prognostic criteria and obviates the need to retrieve ≥12 lymph nodes for accurate prognostication. It identifies those patients most likely to develop recurrent disease within 3 years after curative surgery and, thus, those most likely to benefit from adjuvant treatment. Cancer 2012. © 2012 American Cancer Society.
Click here for entire article: Lenehan et al., Cancer 2012 (1) (1)
This chart illustrates the ability of the 5-gene molecular signature to differentiate lymph node-negative, invasive colorectal cancer (CRC) tumors in the external validation set (n = 264) for patients at “low risk” versus patients at “high risk” of developing a recurrence within 36 months after surgery. CI indicates confidence interval; HR indicates hazard ratio.
Downstate medical alumni and students! We would love to feature your peer-reviewed publications and presentations given at national conferences. Contact us at firstname.lastname@example.org.
Give to student programs today!